EQ-5D at week 52
| BLISS-52 | BLISS-76 | Pooled | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Placebo (n=287) | Belimumab 1 mg/kg (n=288) | Belimumab 10 mg/kg (n=290) | Placebo (n=275) | Belimumab 1 mg/kg (n=271) | Belimumab 10 mg/kg (n=273) | Placebo (n=562) | Belimumab 1 mg/kg (n=559) | Belimumab 10 mg/kg (n=563) | |
| Mean utility (US) change from BL±SE | 0.05±0.01 | 0.04±0.01 | 0.06±0.01 | 0.05±0.01 | 0.06±0.01 | 0.06±0.01 | 0.05±0.01 | 0.05±0.01 | 0.06±0.01 |
| Mobility† | – | 8.79* | 8.07 | – | 0.31 | −0.33 | – | 4.79 | 4.16 |
| Self-care† | – | 4.54 | 3.98 | – | 1.35 | 3.36 | – | 3.04 | 3.70 |
| Usual activities† | – | 1.30 | 4.01 | – | 4.77 | −5.31 | – | 2.92 | −0.29 |
| Pain/discomfort† | – | 0.71 | 9.30* | – | 6.39 | 2.85 | – | 3.38 | 6.33* |
| Anxiety/depression† | – | 4.47 | 3.93 | – | 6.17 | -0.82 | – | 5.28 | 1.71 |
| Mean EQ-5D VAS score change from BL±SE | 9.92±1.18 | 9.77±1.13 | 9.99±1.23 | 7.93±1.34 | 12.11±1.27* | 8.04±1.48 | 8.99±0.89 | 10.88±0.85 | 9.10±0.95 |
*p≤0.05. The p values were obtained from an ANCOVA model for the comparison between each belimumab treatment group and the placebo group.
†Observed difference from placebo at week 52, %.
ANCOVA, analysis of covariance; BL, baseline; VAS, visual analogue scale.